Brief: Evelo Biosciences Presents Further Positive Data From Phase 1B Clinical Trial Of Edp1815 In Atopic Dermatitis
20/04/2021 21:08
April 20 (Reuters) - Evelo Biosciences Inc EVLO.O :
* EVELO BIOSCIENCES PRESENTS FURTHER POSITIVE DATA FROM
PHASE 1B
CLINICAL TRIAL OF EDP1815 IN ATOPIC DERMATITIS
* EVELO BIOSCIENCES INC - INITIATION OF PHASE 2 TRIAL OF
EDP1815
IN ATOPIC DERMATITIS EXPECTED IN 3Q 2021
Source text for Eikon: ID:nGNX2sdxgT
Further company coverage: EVLO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Evelo Biosciences
See all newsU.S. RESEARCH ROUNDUP- Evelo Biosciences, Nkarta, O'Reilly Automotive
U.S. STOCKS ON THE MOVE-DXC Technology, Nvidia, Lisata Therapeutics
Evelo Bio slumps after skin disease drug fails in mid-stage study
U.S. STOCKS ON THE MOVE-Nvidia, Westlake, North American steel companies
U.S. STOCKS ON THE MOVE-TMC, PayPal, TOMI